Table 7. Correlations between CTC and molecular expression in lung small cell carcinoma.
| Molecular expression | Negative, N (%) | Positive, N (%) | Unknown, N (%) | Correlation coefficient | P |
|---|---|---|---|---|---|
| TTF-1 (10%) | 21 (8.47) | 153 (61.69) | 74 (29.84) | −0.289 | 0.64 |
| Calretinin (5%) | 10 (4.03) | 0.000 | 238 (95.97) | 0.116 | 0.59 |
| CD34 (20%) | 71 (28.63) | 30 (12.10) | 147 (59.27) | 0.289 | 0.11 |
| CD56 (5%) | 33 (13.31) | 202 (81.45) | 13 (5.24) | −0.354 | 0.56 |
| CD68 (30%) | 31 (12.50) | 4 (1.61) | 213 (85.89) | 0.022 | 0.89 |
| CDX2 (50%) | 5 (2.02) | 0.000 | 243 (97.98) | −0.272 | 0.50 |
| c-MET (25%) | 37 (14.92) | 6 (2.42) | 205 (82.66) | −0.031 | 0.87 |
| CgA (10%) | 47 (18.95) | 146 (58.87) | 55 (22.18) | −0.350 | 0.58 |
| CK (10%) | 66 (26.61) | 93 (37.50) | 89 (35.89) | −0.164 | 0.34 |
| CK20 (10%) | 43 (17.34) | 11 (4.44) | 194 (28.23) | −0.120 | 0.52 |
| CK7 (10%) | 49 (19.76) | 142 (57.26) | 57 (22.98) | −0.707 | 0.18 |
| CK8/18 (10%) | 26 (10.48) | 0.000 | 222 (89.52) | 0.230 | 0.71 |
| Desmin (1%) | 7 (2.82) | 0.000 | 241 (97.18) | −0.108 | 0.56 |
| E-cadherin (25%) | 104 (41.94) | 27 (10.89) | 117 (47.185) | 0.464 | 0.50 |
| ER (25%) | 14 (5.65) | 0.000 | 234 (94.35) | −0.102 | 0.58 |
| GATA3 (50%) | 8 (3.23) | 0.000 | 240 (96.77) | −0.667 | 0.22 |
| GATA6 (10%) | 174 (70.16) | 50 (20.16) | 24 (9.68) | −0.171 | 0.44 |
| GPA33 (1%) | 22 (8.87) | 0.000 | 226 (91.13) | −0.036 | 0.85 |
| HER2 (50%) | 35 (14.11) | 15 (6.05) | 198 (79.84) | 0.242 | 0.19 |
| HNF4α (1%) | 12 (4.84) | 0.000 | 236 (95.16) | −0.073 | 0.70 |
| Ki-67 (25%) | 28 (11.29) | 170 (68.55) | 50 (20.16) | −0.095 | 0.98 |
| LCA (10%) | 23 (9.27) | 0.000 | 225 (90.73) | 0.080 | 0.67 |
| MTAP (50%) | 18 (7.26) | 0.000 | 230 (92.74) | −0.373 | 0.54 |
| MUC4 (5%) | 16 (6.45) | 0.000 | 232 (93.55) | 0.419 | 0.48 |
| Napsin A (25%) | 194 (78.23) | 3 (1.21) | 51 (20.56) | −0.152 | 0.91 |
| P40 (10%) | 39 (15.73) | 10 (4.03) | 199 (80.24) | 0.026 | 0.81 |
| P53 (50%) | 56 (22.58) | 159 (64.11) | 33 (13.31) | −0.447 | 0.23 |
| Pou2F3 (1%) | 30 (12.90) | 53 (21.37) | 165 (66.53) | −0.297 | 0.43 |
| PD-L1 (1%) | 136 (54.84) | 58 (23.39) | 54 (21.77) | −0.010 | 0.96 |
| PR (5%) | 17 (6.85) | 2 (0.81) | 229 (92.34) | 0.011 | 0.96 |
| SALL4 (25%) | 133 (53.63) | 25 (10.08) | 90 (36.29) | 0.049 | 0.79 |
| SMARCA4 (25%) | 82 (33.06) | 34 (13.71) | 132 (53.23) | −0.166 | 0.36 |
| Villin (10%) | 32 (12.90) | 0.000 | 216 (87.10) | 0.081 | 0.66 |
| WT-1 (1%) | 41 (16.53) | 0.000 | 207 (83.47) | −0.079 | 0.71 |
| ZEB1 (10%) | 8 (3.22) | 0.000 | 240 (96.77) | −0.167 | 0.43 |
| β-catenin (50%) | 48 (19.35) | 42 (16.94) | 158 (63.71) | −0.046 | 0.80 |
For molecular expression, the percentage in parentheses represents the threshold for positive and negative expressions. CTC, circulating tumor cell; TTF-1, thyroid transcription factor-1; CK, cytokeratin; C-MET, cellular-mesenchymal to epithelial transition factor; LCA, leucocyte common antigen; MTAP, methylthioadenosine phosphorylase; ER, estrogen receptor; PD-L1, programmed cell death ligand 1; PR, progesterone receptor; SALL4, spalt-like transcription factor 4; SMARCA4, SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin; WT-1, Wilms tumor 1; ZEB1, zinc finger E-box binding homeobox 1.